• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于预防儿童呼吸道合胞病毒感染的单克隆抗体：一项网状荟萃分析

Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis.

作者信息

Garegnani Luis, Escobar Liquitay Camila Micaela, Esteban Ignacio, Lenells Mikaela, Russo Chiara, Bruschettini Matteo, Franco Juan Va

机构信息

Associate Cochrane Centre, Universidad Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Gavi, the Vaccine Alliance, 1218 Geneva, Switzerland.

出版信息

Cochrane Database Syst Rev. 2025 Aug 20;8(8):CD016224. doi: 10.1002/14651858.CD016224.

DOI:10.1002/14651858.CD016224
PMID:40832903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12365943/
Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the comparative effectiveness of monoclonal antibodies (mAbs) for preventing respiratory syncytial virus (RSV) infection in children, and to evaluate the relative rankings for benefits and harms of mAbs for preventing RSV in children.

摘要

这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估单克隆抗体（mAbs）预防儿童呼吸道合胞病毒（RSV）感染的相对有效性，并评估mAbs预防儿童RSV感染的获益与危害的相对排序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9291/12365943/94c26d96bcfa/nCD016224-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9291/12365943/94c26d96bcfa/nCD016224-FIG-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9291/12365943/94c26d96bcfa/nCD016224-FIG-01.jpg

相似文献

1
Monoclonal antibodies for preventing respiratory syncytial virus infection in children: a network meta-analysis.用于预防儿童呼吸道合胞病毒感染的单克隆抗体：一项网状荟萃分析
Cochrane Database Syst Rev. 2025 Aug 20;8(8):CD016224. doi: 10.1002/14651858.CD016224.
2
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.用于降低儿童呼吸道合胞病毒感染风险的单克隆抗体。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD006602. doi: 10.1002/14651858.CD006602.pub4.
3
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒（RSV）毛细支气管炎的免疫预防作用：亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
4
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒（RSV）感染。
Cochrane Database Syst Rev. 2025 Jul 23;7(7):CD013757. doi: 10.1002/14651858.CD013757.pub3.
5
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.用于预防婴儿和儿童呼吸道合胞病毒的单克隆抗体：系统评价和网络荟萃分析。
JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023.
6
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.使用帕利珠单抗对儿童进行呼吸道合胞病毒（RSV）免疫预防：一项系统评价与经济学评估
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. doi: 10.3310/hta12360.
7
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2010 Feb 17(2):CD007743. doi: 10.1002/14651858.CD007743.pub2.
8
Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.呼吸道合胞病毒疾病负担及尼塞韦单抗预防和保护婴儿疾病效用的专家共识。
World J Pediatr. 2025 Jun 28. doi: 10.1007/s12519-025-00926-2.
9
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2014 May 22(5):CD007743. doi: 10.1002/14651858.CD007743.pub5.
10
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒（RSV）感染。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2.

本文引用的文献

1
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.呼吸道合胞病毒疫苗接种和免疫预防：实现保护幼儿的潜力。
Lancet. 2024 Sep 21;404(10458):1157-1170. doi: 10.1016/S0140-6736(24)01699-4. Epub 2024 Sep 9.
2
Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs-reducing global inequity.为低收入和中等收入国家的儿童提供高效长效呼吸道合胞病毒单克隆抗体——减少全球不平等现象。
Lancet Glob Health. 2024 Oct;12(10):e1582-e1583. doi: 10.1016/S2214-109X(24)00258-4. Epub 2024 Jul 24.
3
Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination.
保护婴儿免受呼吸道合胞病毒疾病侵害：长效单克隆抗体与母体疫苗接种的影响及成本效益比较
Lancet Reg Health Eur. 2024 Jan 8;38:100829. doi: 10.1016/j.lanepe.2023.100829. eCollection 2024 Mar.
4
Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.在 COVID-19 大流行期间，幼儿呼吸道合胞病毒全球住院负担的变化：系统分析。
Lancet Infect Dis. 2024 Apr;24(4):361-374. doi: 10.1016/S1473-3099(23)00630-8. Epub 2023 Dec 20.
5
Nirsevimab-alip.奈赛韦单抗-阿利泼素
Clin Ther. 2023 Nov;45(11):1159-1160. doi: 10.1016/j.clinthera.2023.10.001. Epub 2023 Oct 31.
6
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《妊娠期使用辉瑞呼吸道合胞病毒疫苗预防婴儿呼吸道合胞病毒相关下呼吸道疾病：免疫实践咨询委员会建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Oct 13;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1.
7
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《使用尼赛珠单抗预防婴幼儿呼吸道合胞病毒疾病：免疫实践咨询委员会的建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920-925. doi: 10.15585/mmwr.mm7234a4.
8
Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.帕利珠单抗预防高风险住院的婴幼儿呼吸道合胞病毒感染。
Pediatrics. 2023 Jul 1;152(1). doi: 10.1542/peds.2023-061803.
9
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.用于预防婴儿和儿童呼吸道合胞病毒的单克隆抗体：系统评价和网络荟萃分析。
JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023.
10
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.尼塞利珠单抗预防早产儿和足月儿呼吸道合胞病毒下呼吸道感染的疗效，以及对伴有先天性心脏病和慢性肺部疾病的婴儿的药代动力学外推：一项随机对照试验的汇总分析。
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.